Skip to main content
. Author manuscript; available in PMC: 2012 Apr 4.
Published in final edited form as: Leuk Res. 2010 Sep 15;35(3):310–316. doi: 10.1016/j.leukres.2010.06.010

Table 5.

Comparison of normal controls with AML patients pre-treatment.

Subject/patient SUVmean SUVmax CV Percent of bone marrow with SUV greater than 8
Normal controls (n = 10) 1.87 9.9 0.89 1
CR pre-treatment (n = 1) 2.02 14.9 0.83 1
RD pre-treatment (n = 1) 3.17 28.4 1.12 11